First Australian Patients Prescribed Endoca CBD Products
- First Australian patient prescribed THC Global medicinal cannabis product supplied from Endoca's CBD and CBD+CBDa product range
- THC Global is building strong supply chain for imported products in anticipation of launch of THC Global's proprietary manufactured products in 2019
- Endoca CBD+CBDa product range imported by THC Global is GMP Certified
- Ongoing patient and prescriber engagement by THC Global expected to support increased domestic demand
Through completion of this supply, THC Global has verified its supply line from manufacturer through to patient under federal Authorised Prescriber and Special Access Schemes as well as relevant state regulations.
THC Global is currently importing four products from Endoca's range, being its CBD oil in 3% and 15% concentrations, and Endoca's unique CBD+CBDa oils also in 3% and 15% concentrations.
The Company is building patient and prescriber awareness, including sponsoring educational events to highlight the benefits of treatment with medicinal cannabis and the pathways to access product in Australia. As awareness increases within the domestic market, THC Global expects to see corresponding increases in revenue generating product sales.
Documentation which doctors and other prescribers can use to assist in prescribing Endoca's products in Australia under the Authorised Prescriber Scheme and Special Access Schemes can be accessed by registering on the Medicinal Cannabis Medicines Portal (http://mcmp.com.au/).
Enquiries can be directed to THC Global's medical outreach team at email@example.com.
THC Global's Chief Executive Officer, Ken Charteris, commented:
"The ability to secure supply of high-quality GMP certified medicinal cannabis products to domestic patients is a key bridge to implementation of THC Global's 'Farm to Pharma' model.
We continue to build out our domestic infrastructure in Australia under our 'Farm to Pharma' model - research, growing, manufacture and supply."
About THC Global Group Limited
THC Global Group Limited (ASX:THC) (OTCMKTS:HDRPF) (FRA:9TH) operates under a 'Farm to Pharma' pharmaceutical model, now holding all three key cannabis licences being a Cannabis Research Licence, a Medicinal Cannabis Licence (Cultivation), and a Manufacture Licence through its domestic medicinal cannabis subsidiaries THC Pharma and Canndeo. THC Global has secured a significant cannabis growing capacity over multiple cultivation projects and owns a pharmaceuticals bio-manufacturing facility with attached testing and product development laboratory. THC Global is in prime position to commence medicinal cannabis production to service both domestic patients and the global export market. THC Global is active globally with operations in Australia, New Zealand, and Canada and partnerships across Europe, Asia, and the Middle East. In addition to its core Australian medicinal cannabis assets, THC Global has a significant Canadian presence – both in cannabis and in hydroponics equipment. THC Global's Canadian cannabis operation, Vertical Canna, holds property in Nova Scotia, Canada being developed into a large scale cannabis production site. THC Global's hydroponics equipment division, Crystal Mountain, is a revenue generating manufacturer, wholesaler, and retailer of hydroponic equipment and supplies.
THC Global Group Limited